DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsAntineoplastic AgentsCisplatinCombined Modality TherapyCell Line, TumorDrug Resistance, NeoplasmChemotherapy, AdjuvantRemission InductionTreatment OutcomePaclitaxelApoptosisCaspase 12Breast NeoplasmsDisease-Free SurvivalCyclophosphamideTumor Suppressor Protein p53Survival AnalysisDrug Administration ScheduleNeoadjuvant TherapyNeoplasm StagingSurvival RateEtoposideLung NeoplasmsHead and Neck NeoplasmsFluorouracilAntineoplastic Agents, PhytogenicVincristineCarcinoma, Squamous CellCardiomyopathiesDaunorubicinCytarabineCarboplatinMitochondria, HeartVinblastinePrognosisIfosfamideDNA DamageCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, AcuteDeoxycytidineNeoplasm MetastasisTumor Markers, BiologicalMyocardiumRNA, Small InterferingHeartRNA, MessengerNeoplasm Recurrence, LocalSignal TransductionGene Expression Regulation, NeoplasticDose-Response Relationship, DrugNeutropeniaMethotrexateRadiotherapy, AdjuvantAdenocarcinomaTime FactorsBleomycinEnzyme InductionChemoradiotherapyTumor BurdenPrecursor Cell Lymphoblastic Leukemia-LymphomaMitoxantroneKaplan-Meier EstimateFollow-Up StudiesRadiotherapyGranulocyte Colony-Stimulating FactorRadiotherapy DosageInfusions, IntravenousIdarubicinNeoplasmsSalvage TherapyBone NeoplasmsHypopharyngeal NeoplasmsAnthracyclinesTumor Necrosis Factor-alphaLaryngectomyAntimetabolites, AntineoplasticLeukopeniaTransplantation, AutologousDisease ProgressionLeukemia, MyeloidP-GlycoproteinNasopharyngeal NeoplasmsPrednisoneProspective StudiesBrain NeoplasmsEpirubicinTesticular NeoplasmsOvarian NeoplasmsMelphalanBridged CompoundsLymphatic MetastasisAntibodies, MonoclonalMaximum Tolerated DoseXenograft Model Antitumor AssaysOrganoplatinum CompoundsAntibodies, Monoclonal, Humanized